We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.
The National Institutes of Health (NIH) and a panel of distinguished international liver pathologists showcased how Artificial Intelligence (AI) is revolutionizing the evaluation of liver fibrosis in metabolic dysfunction-associated steatohepatitis (MASH)